

# Contents

---

<b>Contributors</b>	<b>xi</b>
<b>Preface</b>	<b>xv</b>
<b>1. Platelet Biology: The Role of Platelets in Hemostasis, Thrombosis and Inflammation</b>	<b>1</b>
<i>Richard C. Becker</i>	
Introduction . . . . .	1
Platelet: Structural Anatomy . . . . .	1
Platelet: Functional Anatomy . . . . .	3
Inflammation and Thrombosis . . . . .	20
Platelet RNA and Proteomics . . . . .	23
Summary . . . . .	23
References . . . . .	23
<b>2. Thromboxane Antagonists</b>	<b>37</b>
<i>Brian R. Dulin and Steven R. Steinhubl</i>	
Introduction . . . . .	37
Biosynthesis and Function of Thromboxane A <sub>2</sub> . . . . .	37
Aspirin . . . . .	38
Aspirin's Mechanism of Action . . . . .	39
Aspirin in Acute Coronary Syndromes . . . . .	41
Aspirin in Secondary Prevention . . . . .	42

Aspirin in Primary Prevention . . . . .	42
Aspirin in Percutaneous Coronary Interventions . . . . .	45
Aspirin Pharmacodynamics and Dosing . . . . .	45
Aspirin Resistance . . . . .	46
Adverse Effects of Aspirin . . . . .	48
NO-Aspirin . . . . .	49
Thromboxane Synthase Antagonist . . . . .	50
Thromboxane Receptor Antagonist . . . . .	52
Dual Thromboxane Synthase/Receptor Antagonist (Modulators) . . . . .	53
Conclusion . . . . .	54
References . . . . .	54
<b>3. Glycoprotein IIb/IIIa Inhibitors</b>	<b>65</b>
<i>Sam J. Lehman, Derek P. Chew and Harvey D. White</i>	
Introduction . . . . .	65
Abciximab . . . . .	69
Small Molecule GP IIb/IIIa Inhibitors . . . . .	73
Oral GP IIb/IIIa Inhibitors . . . . .	76
New Trials of GP IIb/IIIa Inhibitors . . . . .	77
Summary/Conclusions . . . . .	78
Summary Box . . . . .	79
References . . . . .	80
<b>4. ADP Receptor Antagonists</b>	<b>87</b>
<i>Juhana Karha and Christopher P. Cannon</i>	
Adenosine Diphosphate Receptor . . . . .	87
Ticlopidine . . . . .	88
Clopidogrel — General Considerations . . . . .	95
Clopidogrel in Atherothrombotic Disease . . . . .	98
Clopidogrel in Cerebrovascular Disease . . . . .	100
Clopidogrel in Cardiovascular Disease . . . . .	101
Considerations with Percutaneous Coronary Intervention . . . . .	109
Novel Oral ADP Receptor Antagonists . . . . .	112
Intravenous ADP Receptor Antagonists . . . . .	114

Future Directions . . . . .	115
Summary . . . . .	116
References . . . . .	116
<b>5. Monitoring Antiplatelet Therapy</b>	<b>125</b>
<i>Paul Harrison and Alan D. Michelson</i>	
Introduction . . . . .	125
History of Platelet Function Testing and Overview of Currently Available Tests . . . . .	125
Monitoring Antiplatelet Therapy . . . . .	136
Conclusions . . . . .	146
References . . . . .	146
<b>6. Platelet Genomics</b>	<b>159</b>
<i>Brian K. Jefferson, Kandice Kottke-Marchant and Eric J. Topol</i>	
Introduction . . . . .	159
Platelet Surface Receptor Polymorphisms . . . . .	160
Specific Receptor Polymorphisms . . . . .	163
Platelet Surface Receptor Polymorphisms and Pharmacogenomics . . . . .	167
Genomic Analysis in Platelets . . . . .	170
Novel Methods for Platelet Genomic Analysis . . . . .	170
Platelet Proteomics . . . . .	171
Platelet Transcription . . . . .	176
Platelet Transcriptome . . . . .	180
Conclusion . . . . .	183
References . . . . .	184
<b>7. Future Strategies for the Development of Antiplatelet Drugs</b>	<b>197</b>
<i>Robert A. Harrington</i>	
Introduction . . . . .	197
Arterial Thrombosis, Platelets, Cardiovascular Disease, and Antiplatelet Therapies . . . . .	197

Drug Development . . . . .	199
Antiplatelet Drug Development . . . . .	202
Future Directions . . . . .	211
References . . . . .	211
<b>Index</b>	<b>217</b>